Nocion Therapeutics has announced the initiation of the Phase 2b ASPIRE clinical trial of its NOC-110 inhaled dry powder taplucainium (formerly NTX-1175) in patients with chronic cough. Earlier this year, the company said that it had raised $62 million to conduct the trial, which is expected to enroll approximately 325 patients and will evaluate two dose levels of NOC-110 versus placebo.
The company recently named Joan Shaw as Senior VP, Clinical Operations, and appointed Catherine Bonuccelli to the scientific advisory board as it was preparing for the Phase 2b trial.
Nocion CEO Rick Batycky commented, “Dosing of the first patient in the ASPIRE clinical study is a significant milestone for Nocion. Taplucainium represents a novel approach to the treatment of chronic cough with the potential to deliver enhanced efficacy and reduced side effects to more than 8 million patients per year just in the United States.”
Read the Nocion Therapeutics press release.
